ESR1 and neoplasm: This knowledge has been exploited clinically by the development of endocrine therapies, which seek to deprive the hormone dependent tumour cells of oestrogen (E) using aromatase inhibitors (AI), or the use of antiestrogens such as tamoxifen or fulvestrant (Fulv) both of which compete with E for the ER.